Governing AI in pharma means fitting machine learning into a GxP world built on validation, data integrity, and traceability. Any model that touches a regulated decision, from manufacturing release to clinical data handling to pharmacovigilance, falls under computer system validation, 21 CFR Part 11, GMP, and ALCOA-plus data-integrity expectations. Regulators now issue draft guidance on AI credibility in the drug lifecycle, demanding risk-based validation, documented model rationale, and human oversight. This playbook translates GxP obligations into concrete controls for model validation, bias assessment in trial populations, audit trails, and the human approval gates that keep AI in pharma inspection-ready.
Machine learning meets a validation-first regulatory world
Pharmaceutical governance was engineered decades before machine learning, around a simple premise: any system influencing product quality or patient safety must be validated, controlled, and reconstructable. That premise does not bend for AI. When a model informs batch release, processes clinical data, or triages adverse-event reports, it enters the scope of computer system validation, current Good Manufacturing Practice, and 21 CFR Part 11 electronic-records and signatures rules. Regulators have signaled clearly that AI is welcome but must be credible: recent draft guidance frames a risk-based credibility assessment scaled to a model's context of use and the consequence of the decision it supports.
The friction is real. Traditional CSV assumes deterministic, testable software with fixed logic. Machine learning models are probabilistic, drift over time, and can be opaque. ALCOA-plus data-integrity principles, that data be attributable, legible, contemporaneous, original, accurate, and complete, consistent, enduring and available, must extend to training data, model versions, and inference logs. Governance leaders resolve this by treating models as controlled, versioned artifacts with documented rationale, defined human oversight, and monitoring that catches drift before it reaches a regulated decision. They also maintain a living inventory of every in-scope AI system, its context of use, validation status, and accountable owner, so quality and regulatory teams can answer inspection questions in minutes instead of scrambling to reconstruct what a model does and who signed off on it.
Map each obligation to a concrete AI control
For every regulated use case, translate the governing requirement into a control you can demonstrate to an inspector. The higher the patient-safety or product-quality consequence, the deeper the validation.
| Requirement | What it demands of an AI system | Concrete control |
|---|---|---|
| Computer system validation | Risk-based evidence the model performs as intended for its context of use | Credibility assessment, validation protocol, defined acceptance criteria |
| 21 CFR Part 11 | Trustworthy electronic records and signatures, secure audit trails | Immutable inference and decision logs, access control, e-signature on approvals |
| GMP | Change control and qualification for anything touching production | Model change control, revalidation triggers, qualified deployment pipeline |
| ALCOA-plus data integrity | Traceable, complete, enduring training and inference data | Versioned datasets, data lineage, retained model and prompt versions |
| Bias and fairness | Representative populations, no discriminatory clinical outputs | Subgroup performance testing, trial-population representativeness review |
Build inspection-ready AI governance, not a policy binder
- Adopt a risk-based, context-of-use credibility framework so a model informing batch release gets far deeper validation than one drafting an internal literature summary, and document the rationale for the tier assigned.
- Version and retain everything an inspector could ask for: training datasets, model versions, prompt versions, retrieval sources, and inference logs, with lineage that satisfies ALCOA-plus.
- Place a human approval gate on every consequential output, capturing an accountable approver identity via a Part 11 compliant electronic signature before the output is acted on.
- Test subgroup performance across sex, age, and race or ethnicity for any model touching trial design, recruitment, or clinical decisions, and document representativeness of the underlying population.
- Define revalidation triggers, such as data drift, model updates, or process changes, and wire them into GMP change control so models are re-qualified before, not after, they degrade in a manufacturing or clinical setting.
How AI governance fails an inspection
- Applying one-size validation, either over-validating harmless internal tools into paralysis or under-validating a batch-release model that should have had the deepest scrutiny.
- Treating a model as static after go-live, with no drift monitoring or revalidation trigger, so silent performance decay reaches regulated decisions undetected.
- Broken data integrity: training data or model versions that cannot be reconstructed, failing ALCOA-plus and making the model indefensible in an audit.
- Ignoring bias in trial populations, deploying recruitment or design models trained on unrepresentative cohorts that skew enrollment and undermine both ethics and generalizability.
Evidence your governance holds up
- Share of in-scope models with a completed, context-of-use credibility assessment and current validation status.
- Percentage of consequential outputs passing a documented human approval gate with a captured Part 11 signature.
- Subgroup performance parity across key demographic strata for clinical and recruitment models.
- Time from a detected drift or process-change trigger to completed model revalidation under change control.
Frequently asked questions
Does 21 CFR Part 11 apply to AI models?
Yes, whenever a model creates, modifies, or informs regulated electronic records or decisions. You need secure, attributable audit trails of inputs, model versions, and outputs, plus electronic signatures on approvals. The rigor scales with the model's context of use and the consequence of the decision it supports.
How do we validate a model that keeps changing?
Use a risk-based CSV approach with defined acceptance criteria and a locked, versioned model for production. Treat updates as GMP change-control events requiring revalidation, and monitor for drift with pre-defined triggers so retraining is controlled rather than continuous and undocumented.
What about bias in AI-supported trials?
Test model performance across demographic subgroups and document the representativeness of the training and trial populations. Unrepresentative cohorts produce recruitment and design outputs that skew enrollment, raising ethical and scientific concerns and weakening the generalizability regulators expect.
Related reading
Go deeper on this sector and topic.